Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Iscalimab by Novartis for Lupus Nephritis: Likelihood of Approval
Iscalimab is under clinical development by Novartis and currently in Phase II for Lupus Nephritis. According to GlobalData, Phase II...
Iscalimab by Novartis for Type 1 Diabetes (Juvenile Diabetes): Likelihood of Approval
Iscalimab is under clinical development by Novartis and currently in Phase II for Type 1 Diabetes (Juvenile Diabetes). According to...
Risk adjusted net present value: What is the current valuation of Novartis's Iscalimab?
Iscalimab is a monoclonal antibody commercialized by Novartis, with a leading Phase II program in Lupus Nephritis. According to Globaldata,...
Risk adjusted net present value: What is the current valuation of Novartis's Iscalimab?
Iscalimab is a monoclonal antibody commercialized by Novartis, with a leading Phase II program in Lupus Nephritis. According to Globaldata,...